XBP1 and ovarian carcinoma: In this study, our results showed the expression, prognosis, and relativity to antitumor immunity analyses of immune checkpoints may not be ideal therapeutic targets for ovarian cancer, and XBP1 is a potential coregulator of immune checkpoints in ovarian cancer.